Helix Biopharma Corp.

3-305 Industrial Parkway
Aurora
Ontario
L4G 6X7
Canada

Tel: 905-841-2300-Ext-232
Fax: 905-841-2244

Website: http://www.helixbiopharma.com/

Email: invrelations@helixbiopharma.com

Show jobs for this employer

276 articles with Helix Biopharma Corp.

  • Helix BioPharma Corp. today announced that Dr. Krzysztof Saczek has been appointed as a member of the Board of Directors of the Company effective immediately.

  • Helix BioPharma Corp., an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced that it has appointed Marcum LLP as the Company's new auditor, replacing BDO Canada LLP.

  • Helix BioPharma Corp., a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced its financial results for the fiscal third quarter ended April 30, 2021.

  • Helix BioPharma Corp. announced that it has closed the first tranche of the previously announced private placement pursuant to the convertible security funding agreement with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC for gross proceeds of CAD$3.5 million.

  • Helix BioPharma Corp. an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive convertible security funding agreement with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC

  • Helix BioPharma Corp. an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange

  • Helix BioPharma Corp. an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2021.

  • Helix BioPharma Corp. (TSX:HBP) , a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr. Frank Gary Renshaw to the Companys Scientific Advisory Board.

  • Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2021.

  • Helix BioPharma Corp. (TSX:HBP) a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.

  • Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG for the Companys remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A.

  • Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, announced its fiscal 2021 first quarter results for the period ending October 31, 2020.

  • RICHMOND HILL, ON / ACCESSWIRE / December 4, 2020 / Helix BioPharma Corp. ( TSX:HBP ) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $1,100,000. The terms of the placement are for the purchase of units at $0.50 per unit. Each unit is comprised of one com

  • Helix BioPharma Corp. announced that it has signed a definitive share purchase agreement with CAIAC Fund Management AG, as designed trustee of HIO Fund, to purchase Helix's remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A., for gross proceeds of PLN 6,700,000.

  • Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, announced its financial results for the 2020 fiscal year ended July 31, 2020.

  • Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020

  • Helix BioPharma today announced that it has extended its collaboration agreement with Moffitt Cancer Center ("Moffitt") for an additional year.

  • Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2020. OVERVIEW The Company reported a consolidated net loss and total comprehensive loss of $2,594,000 ($0.02 loss per common share) and $7,060,000 ($0.05 loss per common share), respectively for the three and nine-m

  • Helix BioPharma Corp. (TSX: HBP) (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has entered into a non-binding term sheet to divest the remaining shares it holds in its Polish subsidiary (the “ Divestment ”), Helix Immuno-Oncology S.A. (“ HIO ”), representing approximately

  • Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at Proactive One2One Virtual Investor Forum on June 23, 2020. Dr. Heman Chao, Chief Executive Officer of Helix is scheduled to present on Tuesday, June 23 rd at approximately 1:20pm Eastern Time. The presentation will be web